Novo Nordisk A/S NOVO NORDISK ORD SHS CLASS B
Novo Nordisk A/S NOVO NORDISK ORD.../ DK0062498333 /
0QIU
24/05/2024 18:34:50
|
Var.
-
|
Volume |
Denaro16:55:03 |
Lettera16:55:03 |
Capitalizzazione di mercato |
Dividend Y. |
Rapporto P/E |
937.40DKK
|
-
|
1.26 mill. Fatturato: 91.14 mill. |
-Quantità in denaro: - |
-Quantità in lettera: - |
2818.42 bill.DKK |
1.15% |
43.95 |
Descrizione business
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk markets its products in more than 180 countries.
Consiglio di amministrazione & Consiglio di sorveglianza
CEO |
Lars Fruergaard Jørgensen |
Consiglio di amministrazione |
Karsten Munk Knudsen, Camilla Sylvest, Doug Langa, Henrik Wulff, Ludovic Helfgott, Marcus Schindler, Martin Horst Lange, Maziar Mike Doustdar, David Moore, Tania Sabroe |
Consiglio di sorveglianza |
Helge Lund, Andreas Fibig, Henrik Poulsen, Kasim Kutay, Laurence Debroux, Martin Mackay, Mette Bøjer Jensen, Sylvie Grégoire, Thomas Rantzau, Elisabeth Dahl Christensen, Liselotte Hyveled, Christina Law |
Dati aziendali
Name: |
Novo Nordisk AS |
Indirizzo: |
Novo Alle 1,2880 Bagsvaerd, Denmark |
Telefono: |
+45-4444-8888 |
Fax: |
- |
E-mail: |
-
|
Internet: |
www.novonordisk.com/ |
Industria: |
Healthcare |
Settore: |
Pharmaceutical Industry |
Sub settore: |
Pharmaceuticals |
Fine dell'anno finanziario: |
31/12 |
Flottante libero: |
66.64% |
Data dell'IPO: |
04/01/1982 |
Company calendar
CW 45 | 06/11/2024
Interim Report 3rd Quarter/9 Months
|
CW 6 | 05/02/2025
Annual Report
|